Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy)

Journal of Medical Virology

Volumn 82, Issue 12, 2010, Pages 2027-2031

  Halfon, Philippe ^a   Pérusat, Sophie ^b   Bourlière, Marc ^c   Bronowicki, Jean Pierre ^d   Trimoulet, Pascale ^e   Benhamou, Yves ^f   Leroy, Vincent ^g   Marcellin, Patrick ^h   Foucher, Juliette ^e   Penaranda, Guillaume ^a   Chêne, Geneviève ^b,e   Couzigou, Patrice ^e  

^a HÔPITAL AMBROISE PARÉ   (France)

^b INSERM   (France)

^c HÔPITAL SAINT JOSEPH   (France)

^d CHU NANCY BRABOIS   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g HÔPITAL MICHALLON   (France)

^h BEAUJON HOSPITAL   (France)

Author keywords

Hepatitis C virus; Neutralizing antibody; Non responders; Second line treatment

Indexed keywords

ALPHA INTERFERON; NEUTRALIZING ANTIBODY; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; TREATMENT FAILURE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-GAMMA, RECOMBINANT; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 78049438289     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21909     Document Type: Article

References (26)

1. Antonelli G, Currenti M, Turriziani O, Dianzani F. 1991. Neutralizing antibodies to interferon-alpha: Relative frequency in patients treated with different interferon preparations. J Infect Dis 163: 882-885.
2. Antonelli G, Giannelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F, Pistello M, Roffi L, Pastore G, Chemello L, Dianzani F. 1996. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin Exp Immunol 104: 384-387.
3. Basso M, Torre F, Grasso A, Percario G, Azzola E, Artioli S, Blanchi S, Pelli N, Picciotto A. 2007. Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. Dig Liver Dis 39: 47-51.
4. Berg T, Hopf U, Schuff-Werner P. 2001. Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-alpha in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-alpha. Am J Gastroenterol 96: 612-614.
5. Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, Reiser M, Marschal O, Steffen M, Manns MP, Wedemeyer H. 2006. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study. J Hepatol 44: 291-301.
6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
7. Hoofnagle JH. 2002. Course and outcome of hepatitis C. Hepatology 36: S21-S29.
8. Jorns C, Holzinger D, Thimme R, Spangenberg HC, Weidmann M, Rasenack J, Blum HE, Haller O, Kochs G. 2006. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha. J Med Virol 78: 74-82.
9. Leroy V, Baud M, de Traversay C, Maynard-Muet M, Lebon P, Zarski JP. 1998. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol 28: 375-381.
10. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, Muir AJ, McHutchison JG. 2010. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138: 2307-2314.
11. Micallef JM, Kaldor JM, Dore GJ. 2006. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J Viral Hepat 13: 34-41.
12. Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, Angarano G, Dianzani F, Pastore G. 1993. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 13: 146-150.
13. Milella M, Antonelli G, Santantonio T, Giannelli G, Currenti M, Monno L, Turriziani O, Pastore G, Dianzani F. 1995. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. Hepatogastroenterology 42: 201-204.
14. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Goncales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J. 2009. Peginterferon alfa-2b and ribavirin: Effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 136: 1618.e2-1628.e2.
15. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 138: 1338-1345.
16. Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, Ravizza D, Angeli G, Dianzani F, Mancia G. 1995. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology, and management. Hepatology 21: 645-649.
17. Seeff LB. 2002. Natural history of chronic hepatitis C. Hepatology 36: S35-S46.
18. Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, Anderson F, Kaita K, Simonyi S, Balshaw R, Lee SS. 2006. Peginterferon alfa-2a (40kDa) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 55: 1631-1638.
19. Shiffman ML. 2004. Management of patients with chronic hepatitis C virus infection and previous nonresponse. Rev Gastroenterol Disord 4: S22-S30.
20. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
21. Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, Capanni M, Esperti F, Forte P, Guadagnino V, Mari T, Marino N, Milani S, Pasquazzi C, Rosina F, Tacconi D, Toti M, Zignego AL, Messerini L, Stroffolini T. 2006. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 130: 1098-1106.
22. Thomas DL, Seeff LB. 2005. Natural history of hepatitis C. Clin Liver Dis 9: 383-398.
23. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
24. van der Eijk AA, Vrolijk JM, Haagmans BL. 2006. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. N Engl J Med 354: 1323-1324.
25. Veldt BJ, Brouwer JT, Adler M, Nevens F, Michielsen P, Delwaide J, Hansen BE, Schalm SW. 2003. Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with ribavirin and interferon in 121 patients in the Benelux [ISRCTN53821378]. BMC Gastroenterol 3: 24.
26. WHO. 2000. Hepatitis C, Fact Sheet No. 164.